Close Menu
  • FDA
  • Conferences
    • AACR
    • ASBRS
    • ASCO
    • SABCS
    • ASH
    • ESMO
    • MOASC
    • Upcoming Oncology Conferences
  • Cancers
    • Breast Cancer
    • Prostate Cancer Treatment
    • Lung Cancer Treatment
    • Gastrointestinal Cancer Treatment
    • Melanoma Skin Cancer Treatment
    • Non-Hodgkin Lymphoma
    • Kidney
    • Acute Lymphoblastic Leukemia
    • Acute Myelogenous Leukemia
    • Bone Metastases
    • Brain
    • Business Management
    • Cervical
    • Chronic Lymphocytic Leukemia
    • Chronic Myelogenous Leukemia
    • Colorectal
    • COVID-19
    • General
    • Genitourinary
    • Head and Neck
    • Help
    • Hematologic Malignancies
    • Hodgkin Lymphoma
    • Imaging
    • Immunotherapy
    • Liver
    • Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Disease
    • News
    • Non-Small Cell Lung Cancer
    • Other
    • Ovarian
    • Pancreatic
    • Patient Resources
    • Pediatric
    • Sarcoma
    • Sickle Cell
    • Small Cell Lung Cancer
    • Supportive Care
    • Testicular
    • Urology
    • Uterine
  • About
  • Contact
  • Advertise
    • Advertising & Services – Media Kit 2025 OncologyTube.com
    • Oncology Press Release Distribution
Advertisement
X (Twitter) LinkedIn Facebook
X (Twitter) LinkedIn Facebook YouTube
OncologyTube
  • FDA
  • Conferences
    • AACR
    • ASBRS
    • ASCO
    • SABCS
    • ASH
    • ESMO
    • MOASC
    • Upcoming Oncology Conferences
  • Cancers
    • Breast Cancer
    • Prostate Cancer Treatment
    • Lung Cancer Treatment
    • Gastrointestinal Cancer Treatment
    • Melanoma Skin Cancer Treatment
    • Non-Hodgkin Lymphoma
    • Kidney
    • Acute Lymphoblastic Leukemia
    • Acute Myelogenous Leukemia
    • Bone Metastases
    • Brain
    • Business Management
    • Cervical
    • Chronic Lymphocytic Leukemia
    • Chronic Myelogenous Leukemia
    • Colorectal
    • COVID-19
    • General
    • Genitourinary
    • Head and Neck
    • Help
    • Hematologic Malignancies
    • Hodgkin Lymphoma
    • Imaging
    • Immunotherapy
    • Liver
    • Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Disease
    • News
    • Non-Small Cell Lung Cancer
    • Other
    • Ovarian
    • Pancreatic
    • Patient Resources
    • Pediatric
    • Sarcoma
    • Sickle Cell
    • Small Cell Lung Cancer
    • Supportive Care
    • Testicular
    • Urology
    • Uterine
  • About
  • Contact
  • Advertise
    • Advertising & Services – Media Kit 2025 OncologyTube.com
    • Oncology Press Release Distribution
Subscribe
OncologyTube
Home » Podcast – Kana Wu, MD, PhD @HarvardChanSPH @DanaFarber @HSPHNutrition #ColorectalCancer #Cancer #Research Pattern of DNA Damage Links Colorectal Cancer and Diet High in Red Meat
Colorectal

Podcast – Kana Wu, MD, PhD @HarvardChanSPH @DanaFarber @HSPHNutrition #ColorectalCancer #Cancer #Research Pattern of DNA Damage Links Colorectal Cancer and Diet High in Red Meat

EditorBy EditorAugust 30, 2021No Comments4 Mins Read
Twitter LinkedIn Facebook Email
Share
Twitter LinkedIn Facebook Email

Ask about FDA oncology approvals, clinical trials, and treatment guidelines.

Kana Wu, M.D., Ph.D., Principal Research Scientist in the Department of Nutrition at Harvard T. H. Chan School of Public Health, Member of the Dana-Farber/Harvard Cancer Center (DF/HCC, program affiliation: Cancer Epidemiology and Gastrointestinal Malignancies), Member of the Working Group for the IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 114 (Red Meat and Processed Meat) Speaks about the Pattern of DNA Damage Links Colorectal Cancer and Diet High in Red Meat.

Link to Article:
https://www.cancer.gov/news-events/cancer-currents-blog/2021/red-meat-colorectal-cancer-genetic-signature

A diet heavy in red and processed meats has been related to colorectal cancer in several studies, but it’s unclear how eating cheeseburgers, hot dogs, and lamb chops may contribute to the disease’s development.

New insights might be on the way shortly. Kana Wu, M.D., Ph.D., of the Harvard T.H. Chan School of Public Health’s Department of Nutrition, designed a study to see if frequent consumption of red and processed meat, a known risk factor for colorectal cancer, may leave a specific pattern of DNA damage in colorectal tumors, known as a mutational signature.

A team of researchers, working with Dr. Wu, discovered such a pattern in the colorectal cancers of patients who reported eating a lot of red and processed meat in their diets. Specific chemicals generated in the body following the ingestion of red meat triggered this “alkylating” harm.

These mutational traces are similar to a criminal’s fingerprints left at a crime scene. Researchers can use these patterns to track down the mutations that contributed to the development of a tumor.

The identification of an alkylating mutational signature linked to red and processed meat intake “further implicates” food in the development of colorectal cancer, according to Marios Giannakis, M.D., Ph.D., also of the Dana-Farber Cancer Institute and Harvard Medical School, who co-led the study.

To reach their conclusions, the researchers examined tumor DNA from hundreds of patients with colorectal cancer who had supplied detailed information about their diet in the years leading up to their diagnosis.

Dr. Giannakis highlighted that understanding how red and processed meat may induce genetic damage that leads to colorectal cancer might lead to new ways to prevent colorectal cancer, diagnose it early, and treat it with targeted treatments. One possible strategy to prevention, he added, may be to identify those who are prone to alkylating damage and advise them to restrict their red meat consumption.

According to Dr. Straif, who was not involved in the study, the findings “shed more light” on the relationship between red and processed meat and colon cancer. “It adds to the weight of the evidence.”

The evidence is growing.

For years, there has been mounting evidence linking red and processed meat to the development of colon cancer. IARC categorized processed beef as a human carcinogen (Group 1) in 2015, based on data from 800 research. This means that there is enough evidence to infer that it may cause cancer in people. Because the data for red meat was less conclusive, the International Agency for Research on Cancer categorized it as a possible carcinogen (Group 2A).

Researchers are still working to figure out how red and processed meat cause cancer. Preservatives added to processed meats, such as nitrates and nitrites, have been shown in certain studies to create chemicals that harm DNA. Other research has looked at how chemicals formed when red meat is cooked at high temperatures, such as when grilling, promote the buildup of cancer-causing mutations.

Scientists can use DNA analysis to find mutational signals that can help them figure out where the DNA damage that started a tumor’s development came from. Diverse mutational processes are reflected by different mutational signatures, which are unique patterns of DNA damage. Some mutational signatures are caused by physiological processes like DNA repair or oxidative stress, while others are caused by environmental factors like UV radiation or cigarette smoking.

Alkylating signatures are a sort of mutational signature that occurs when genetic material is destroyed by substances that cause DNA lesions (a process known as alkylation). When alkylation lesions are not adequately healed, a particular pattern of mutational damage might occur.

The use of mutational signatures to deduce correlations from epidemiologic research is becoming more common. Scientists have discovered unique mutational fingerprints linked to tobacco smoke exposure, for example.

Follow on X (Twitter) Follow on LinkedIn Follow on Facebook Follow on Google News
Share. Twitter LinkedIn Facebook Email

Related Posts

Dr. Joshua G. Cohen, MD, City of Hope - 2026 Cancer Breakthroughs at MOASC Summit

2026 Cancer Breakthroughs: Dr. Joshua Cohen’s Top Takeaways from the MOASC Summit

Breast Cancer 4 Mins Read
2026 Colorectal Cancer Updates ATOMIC BREAKWATER CHALLENGE trials explained by Dr. Jason Zell DO MPH at MOASC

Colorectal Cancer Updates 2026: ATOMIC, BREAKWATER & CHALLENGE Trials

Colorectal 3 Mins Read
Infographic on alcohol-related cancer risks from 2025 US Surgeon General’s Advisory

Alcohol Consumption and Cancer Risk: Insights from the 2025 Surgeon General’s Advisory

Breast Cancer 3 Mins Read
Connect With Us on Social
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube

Latest FDA Oncology Updates

Accepted for Review Oncology Press Release

FDA Accepts NDA for TLX101-Px (Pixclara®) - PR Newswire

FDA Accepts NDA for TLX101-Px (Pixclara®). (PRNewsfoto/Telix Pharmaceuticals ... cancer), and has assigned a PDUFA goal date of September 11, 2026 ...

Filed: Sep 11, 2026 View source on FDA.gov →
ODAC Meeting Oncology FDA ODAC

April 30, 2026: Meeting of the Oncologic Drugs Advisory Committee

Event Title. April 30, 2026: Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement. April 30, 2026 · On This Page · Agenda · Meeting Materials.

Meeting: Apr 30, 2026 View source on FDA.gov →
PDUFA Date Oncology Press Release

Savara Announces the U.S. Food & Drug Administration (FDA) Has ...

Such statements include, but are not limited to, statements related to the target PDUFA action date. Savara may not actually achieve any of the matters ...

View source on FDA.gov →
Approval Heme FDA OCE

FDA approves nivolumab with chemotherapy for Hodgkin lymphoma

This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent ...

View source on FDA.gov →
News Oncology FDA OCE

FDA Oncology Center of Excellence Presents Conversations on ...

FDA Oncology Center of Excellence Presents Conversations on Cancer: Oncology Nurses - Frontliners in Oncology May 6, 2026.

View source on FDA.gov →
News Oncology FDA OCE

FDA Schedules Public Meeting on the Commissioner's National ...

... Oncology Center of Excellence, as well as a presiding officer. Requests to speak are due by April 24 at 11:59 p.m. The FDA is also soliciting written ...

View source on FDA.gov →
Approval GYN FDA.gov

FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.

Approved: Mar 25, 2026 View source on FDA.gov →
Approval Heme FDA.gov

FDA approves nivolumab with chemotherapy for previously untreated Hodgkin lymphoma

On March 20, 2026, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL).

Approved: Mar 20, 2026 View source on FDA.gov →
Recent Posts
  • Does QHS-5132 Signal a Biomarker-Agnostic Shift in Ovarian Cancer Treatment?
  • Is Alisertib the New Standard for Overcoming Resistance in KRAS G12C-Mutant NSCLC?
  • Can Zoldonrasib Redefine Treatment for KRAS G12D NSCLC?
  • Are We Under-Treating PE in Cancer Patients?
  • Is MammaPrint High Risk the New Standard for Guiding Immunotherapy?
X (Twitter) LinkedIn Facebook YouTube
  • FDA
  • Conferences
    • AACR
    • ASBRS
    • ASCO
    • SABCS
    • ASH
    • ESMO
    • MOASC
    • Upcoming Oncology Conferences
  • Cancers
    • Breast Cancer
    • Prostate Cancer Treatment
    • Lung Cancer Treatment
    • Gastrointestinal Cancer Treatment
    • Melanoma Skin Cancer Treatment
    • Non-Hodgkin Lymphoma
    • Kidney
    • Acute Lymphoblastic Leukemia
    • Acute Myelogenous Leukemia
    • Bone Metastases
    • Brain
    • Business Management
    • Cervical
    • Chronic Lymphocytic Leukemia
    • Chronic Myelogenous Leukemia
    • Colorectal
    • COVID-19
    • General
    • Genitourinary
    • Head and Neck
    • Help
    • Hematologic Malignancies
    • Hodgkin Lymphoma
    • Imaging
    • Immunotherapy
    • Liver
    • Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Disease
    • News
    • Non-Small Cell Lung Cancer
    • Other
    • Ovarian
    • Pancreatic
    • Patient Resources
    • Pediatric
    • Sarcoma
    • Sickle Cell
    • Small Cell Lung Cancer
    • Supportive Care
    • Testicular
    • Urology
    • Uterine
  • About
  • Contact
  • Advertise
    • Advertising & Services – Media Kit 2025 OncologyTube.com
    • Oncology Press Release Distribution
© 2026 Copyright Protected Medicus Networks, Inc. Privacy Policy

Type above and press Enter to search. Press Esc to cancel.